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In recent years, the notion that ovarian carcinoma results from ovulation-induced inflammation of the fallopian
tube epithelial cells (FTECs) has gained evidence. However, the mechanistic pathway for this process has not been
revealed yet. In the current study, we propose the mutator protein activation-induced cytidine deaminase (AID) as a
link between ovulation-induced inflammation in FTECs and genotoxic damage leading to ovarian carcinogenesis.
We show that AID, previously shown to be functional only in B lymphocytes, is expressed in FTECs under
physiological conditions, and is induced in vitro upon ovulatory-like stimulation and in vivo in carcinoma-associated
FTECs. We also report that AID activity results in epigenetic, genetic and genomic damage in FTECs. Overall, our
data provides new insights into the etiology of ovarian carcinogenesis and may set the ground for innovative
approaches aimed at prevention and early detection.
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Undoubtedly, cancer is a disease of somatic mutations, genomic
instability, and epigenetic abnormalities. The mechanisms behind these
phenomena remain elusive inmostmalignancies.Multitude of ovulation
cycles has been proposed as a trigger of ovarian cancer [1–3]. The normal
physiological process of ovulation consists of both inflammation and
hormonal fluctuations mediated by cytokines, chemokines and steroidal
hormones present in the follicular fluid (FF) [4,5]. Inflammation is a
common pathway that drives carcinogenesis in several organ systems
[6,7], whereas hormonal signaling pathways play a role in tumor
progression, once genetic aberrations have been initiated. In the pastdecade it has become clear that most gynecological serous papillary
carcinomas originate in the fallopian tube fimbria [8,9], turning the
Neoplasia Vol. 18, No. 2, 2016 AID Mediates Ovulation-Induced Carcinogenic Effects Sapoznik et al. 91research focus to the fallopian tube epithelial cells (FTECs) rather than
the ovarian surface epithelium. To that aim we have previously
developed an ex vivo model system of FTECs [10] which can be
genetically modified [11], immortalized [12] and incubated with human
follicular fluid to simulate the effect of ovulation [13].
Endogenous cytidine deaminases (AID and apolipoprotein B mRNA
editing enzyme, catalytic polypeptide (APOBECs)) attract much
attention in recent literature as possibly responsible for both point
mutations and chromosomal rearrangements in multiple cancer types.
Activation-induced cytidine deaminase (AID, the product of the gene
AICDA) normally mediates somatic hyper-mutation and class-switch
recombination in immunoglobulin genes [14]. It preferentially acts
on cytidine in the consensus sequence ofWRCY orWRC (W = A/T, R =
A/G, Y = C/T) [15], on single-stranded DNA in tissue-specifically
transcribed genes. AID targets co-localize with regions of histone
H3K27 acetylation and super-enhancer activity [16,17]. The deamina-
tion reaction results in uracil residues within the DNA sequence,
triggering the base-excision repair enzyme uracil-DNA-glycosylase
(UNG) to form apurinic/apyrimidinic (AP) sites. When replication
occurs before repair has been completed with high fidelity, C:G→ T:A
mutations are incorporated [18]. In cases where trans-lesion DNA
polymerases are absent, the stalled replication fork collapses, resulting in
double-strand DNA breaks and chromosomal rearrangements
[14,19,20]. In addition, as deamination of 5-methylcytidine (5 mC)
results in the formation of thymidine, AID has been implicated in global
genomic hypomethylation [21–23].
AID is expressed mainly in B-lymphocytes, where it also has
non-immunoglobulin targets, including genes that are tightly related to
lymphomagenesis [24,25]. Its activity in epithelial tissues has been
previously described, and shown to be induced by inflammatory stimuli as
well as estradiol [26,27]. Asmentioned, both are components of ovulation.
AIDhas been implicated in inflammation-associatedmalignancies [28,29],
such as Helicobacter pylori–induced gastric adenocarcinoma [30,31],
HBV-related hepatocellular carcinoma [32,33] and cholangiocarcinoma
[34], and also in breast carcinoma [35], and malignant melanoma [36].
AID is up-regulated as early as in esophageal intraepithelial squamous
carcinoma, and persists in invasive carcinoma [37]. Its role in gynecological
malignancies has not been studied, and no model has been developed to
study the function of AID in early tumorigenesis.
The apolipoprotein B mRNA editing enzyme, catalytic polypeptide
(APOBEC), is a family of deaminase enzymes involved in restriction of
retroviral and mobile retroelement sequences. APOBEC3 has been
subject to remarkable evolutionary expansion in primates. The preferred
context of most APOBEC3s activity is of 5′ thymidine preceding the
mutated cytidine [38]. The mutational signature of APOBEC3-family
members has been observed in multiple malignancies [39,40] including
breast cancer [41–43]. They act on single-stranded DNA and have a
typical tendency to cluster resulting in catastrophic regional hyper-
mutation, termed ‘kataegis’ [40,44]. Specifically, APOBEC3B (A3B) is
overexpressed in several tumor types, including ovarian carcinoma [45].
In the basis of the current work lies the hypothesis that endogenous
physiological stimuli related to ovulation may drive genetic and genomic
aberrations that lead to serous carcinogenesis. We show that upon
exposure of the fallopian tube fimbria epithelium to hormonal and
inflammatory stimuli, AID is induced. Its activity leads to genomic and
epigenetic modifications, which may play a causal role in ovarian
carcinogenesis. In the current study, we also report increased AID
expression in FTECs adjacent to established tumors in vivo. These
observations suggest a generalized ‘mutagenic field effect’ in the fimbriapriming it to develop serous carcinoma. We therefore propose that AID
is a mechanistic link between ovulation-induced inflammation and early
stages of serous carcinogenesis.
Materials and Methods
Cell Culture
Fresh, grossly normal fallopian tube fimbriae, removed from patients
undergoing gynecological surgery for indications other than ovarian
cancer, were allocated by the Chaim ShebaMedical Center Institutional
Tissue Bank upon approval of the institutional ethics committee. Tissues
were dissociated as previously described [13], and the harvested cells were
N95% pure (repeatedly verified with PAX8 immunostaining). Overall,
more than 30 specimens from different donors were utilized for this
research. Immortalized FTECs (iFTECs) were kindly provided by the
Drapkin lab, Dana-Farber Cancer Institute, Boston, MA, USA [12].
AID overexpressing FTECs (AID-OE FTECs) were produced by
retroviral infection of iFTECs with pMSCVgfp::AID, a gift from
Dr. Nina Papavasiliou (Addgene plasmid # 15925, [46]). Control cells
were produced by retroviral infection of iFTECS with MSCV-IR-
ES-GFP, a gift from Dr. Tannishtha Reya (Addgene plasmid # 20672).
Immunohistochemistry, Immunofluorescence and Immunoblotting
Archival tissues were retrieved from the Department of Pathology at
theChaim ShebaMedical Center with the appropriate ethical committee
approvals. We constructed tissue microarrays (TMAs) of ~30
representative cases (in duplicates) of normal fimbriae of 4 clinical
conditions and of high-grade serous ovarian carcinoma tumors
(HGSOC, see Results section). All slides were simultaneously stained
and scored according to the signal intensity and distribution, ranging
from negative (no staining or faint staining in b10% of cells), to weak
(faint cytoplasmic staining in N10% of cells), moderate (intermediate
cytoplasmic staining of N10% of cells, or strong cytoplasmic staining of
10–50% of cells) and strong (strong cytoplasmic staining of N50% of
cells). AID expression scores are shown in Supplementary Figure 1.
Immunostaining was performed with anti-AID rabbit polyclonal
antibody (Abcam, Burlingame, CA, USA at 1:150 dilution for 1 h at
RT) and anti-p53 mouse monoclonal antibody (clone DO1, EMD-
Millipore, Billerica, MA, USA at 1:70 dilution for 1 h at RT).
Following 2% paraformaldehyde fixation (Electron Microscopy
Sciences, Hatfield, PA, USA) FTECs and AID-OE FTECs were
immunostained with anti-γH2A.X (Millipore, Billerica, MA, USA at
1:1000 dilution, 4°C, ON), followed by incubation with a fluorescent
secondary antibody. Cell positivity was defined as having at least 5
specific nuclear foci.
Anti-AID Rabbit monoclonal antibody (Cell Signaling, Danvers,
MA, USA at 1:120 dilution, 4°C, ON) was used for Western blot.
RNA Extraction and qRT-PCR
Total RNA was extracted using QIAzol reagent (Qiagen, Valencia,
CA, USA) followed by RNeasy clean-up kit (Qiagen) according to
manufacturer's protocol. 1 μg of total RNA was used for reverse
transcription using high capacity cDNA reverse transcription kit (Applied
Biosystems, Grand Island, NY, USA). mRNA concentrations were
assessed using FastStart Universal SYBR Green Master (ROX) (Roche,
Indianapolis, IN, USA) with the following primers: AID: 5′- GGG
AACCCCAACCTCAGTCT, 5′-CCTTGCGGTCCTCACAGAAG,
A3B: 5′-TTGAAAACGAACCCATCCTC, 5′-AGGGGGTCCAG
GATACAAAC, B2M: 5′-TTCTGGCCTGGAGGCTATC, 5′- TCA
GGAAATTTGACTTTCCATTC.
92 AID Mediates Ovulation-Induced Carcinogenic Effects Sapoznik et al. Neoplasia Vol. 18, No. 2, 2016FF Treatment and Drug Intervention
FF was obtained from 16 women undergoing oocyte retrieval (for
reasons other than hormonal infertility) who provided written
informed consent, following approval by the institutional ethics
committee. It was processed as described before and pooled to
overcome batch effects [13]. Serum-supplemented culture medium
was used as control for FF, hence an equivalent concentration of 1%
Ultroser G (PALL Life Sciences, Cergy-Saint-Christophe, France)
was added to the FF [13]. β-estradiol (Sigma Aldrich, St. Louis, MO,
USA) was used at a final concentration of 10 nM for either 4 or 24 h.
Fulvestrant (Sigma Aldrich, St. Louis, MO, USA) was used at a final
concentration of 100 nM. Cells were exposed to the antagonist 24 h
before exposure to FF pool and throughout 4 h of incubation with
FF. TNFα (Sigma Aldrich, St. Louis, MO, USA) was used at a final
concentration of 5 ng/ml for 4 h. Infliximab (Janssen Biotech,
Titusville, NJ, USA) was used at a final concentration of 10 μg/ml for
4 h, and was mixed with the FF pool 1 h prior to the application on
the cells, in order to achieve complete TNFα blockade.
Fluorescence Based In Vitro Deamination Assay
The protocol was adopted and modified from Leonard et al. and is
illustrated in Figure 5A [45]. Untreated control iFTECs, AID-OE
FTECs, or iFTECs incubated with FF pool were lysed in 25 mM
HEPES pH 7.4, 150 mMNaCl, 1 mMMgCl2, 1 mM ZnCl2, 1 mM
EDTA, 0.5% Triton X-100, 10% Glycerol, 1:100 protease inhibitor
Cocktail (Roche Pharmaceuticals, Indianapolis, IN, USA). For each
sample, 550 μg total protein was incubated for 2 h, 37°C in 50 mM
Tris HCl pH 7.4, 10 mM EDTA containing 0.02 unit uracil-DNA
glycosylase (UNG, New England Biolabs, Ipswich, MA, USA), 2 μg
RNase A (Qiagen, Valencia, CA, USA), and 200 pmol of either an
experimental AID motif-containing dual-fluorescent probe (5′[Cy3]
TATTATACTAATGGATTTAT [Cy5]) or control (A3B-motif)
fluorescent probe (5′[Cy3] TATTATTCCGATGGATTTAT
[Cy5]). 4 N NaOH was added for 30 minutes, at 37°C, and then
neutralized with 4 N HCl in 2 M Tris HCl. The 5′ Cy3 and 3′ Cy5
labeling yields fluorescence resonance energy transfer (FRET) as long
as the probe is intact. Deamination of the C nucleotide resulted in
uracil, the subsequent formation of an AP site by UNG and break of
the probe by NaOH. Hence, AID activity leads to loss of the FRET
signal and gain of Cy3 fluorescent signal. Fluorescence was detected
with excitation at 550 nm and emission at 570 nm using Gemini
Microplate Reader (Molecular Devices, Sunnyvale, CA, USA).
Fluorescent signal detected for the AID motif-containing probe was
normalized by the fluorescent signal obtained for the control probe,
and the ratio between treated cells and control cells was calculated.
Quantification of DNA Damage
We used MethylFlash methylated DNA 5 mC quantification kit
(Epigentek, Farmingdale, NY, USA) to examine 5 mC levels in DNA
of AID-OE FTECs, FTECs and iFTECs extracted 20 h following 4-h
incubation with FF pool.
The number of AP sites was measured using OxiSelect Oxidative
DNA Damage Quantitation Kit (Cell Biolabs, San Diego, CA, USA)
in AID-OE FTECs and iFTECs following 4-h exposure to FF pool.
Microarray Analysis
Microarray experiments were performed on AID-OE FTECs and
control cells. For expression profiling total RNA was profiled using
GeneChip PrimeView Human Gene Expression Array (Affymetrix,
Santa Clara, CA, USA), according to the manufacturer's standardprotocols. To study global copy number variations, genomic DNA
was extracted using ZR-Duet DNA/RNA MiniPrep Kit (Zymo
Research, Irvine, CA, USA), and examined using CytoScan HD
Array Kit (Affymetrix, Santa Clara, CA, USA), according to the
manufacturer's standard protocols. The microarray .CEL files were
deposited in GEO.
Bioinformatic Analysis
293 ovarian cancer and matched normal whole exome datasets were
retrieved from The Cancer Genome Atlas (TCGA) database [47]. The
muTect tool [48] was used to identify somatic point mutations with at
least 25× coverage in both the normal and cancer samples. To filter out
only high confidence mutations the ‘t_lod_fstar’ parameter was set to a
threshold of ≥50. For each mutation, the compatibility with the AID
motif was scored. We then implemented a previously published pipeline
for detection of mutagenesis patterns [39]. Briefly, the pipeline includes
two main stages: Mutations' clustering and detection of enriched
mutagenesis pattern in clustered mutations. We clustered the mutations
as described and calculated P-value for each cluster using negative
binomial distribution. For clusters of C:G mutations, enrichment for
AID/APOBECmotifs was calculated. The enrichment was calculated as
the ratio between the numbers of mutations with each motif to the
cluster context.
Statistical Analysis
Data are presented as mean value ± standard error. For RT-PCR
experiments, statistical significance (P b .05) was assessed by either t
test or by Wilcoxon signed-rank test as indicated. Statistically
significant results are highlighted with ‘*’.
Results
AID is Expressed in Fallopian Tube Fimbria Epithelial Cells
To test whether AID is expressed in normal human fallopian tube
fimbriae, we immunostained TMAs of grossly normal fimbriae of
patients undergoing salpingectomy for the following indications: (A)
HGSOC, (B) risk-reducing bilateral salpingo-oophorectomy (RRBSO)
in BRCA mutation carriers, (C) leiomyoma (condition not expected to
affect the FTECs) or (D) ectopic pregnancy (non-malignant pathology
of the tube). AID is indeed expressed in human FTECs, while not in
tubal stromal cells (Figure 1). AID is localizedmainly in the cytoplasm of
the epithelial cells, as observed in B lymphocytes, and in accordance with
previous literature [49]. Age did not significantly correlate with AID
staining score in any of the 4 groups, or when all cases were analyzed
together (Pearson's test, r = 0.41).
The highest expression of AID is seen in normal fallopian tube
sections derived from HGSOC patient (Figure 1, A, G), with 78% of
the patients staining positive to some degree. Serous tubal intraepithelial
carcinoma (STIC) precursor lesions can be highlighted within the
fimbria of HGSOC patient by strong staining for p53 (nuclear stain,
Figure 1C), whereas the adjacent normal epithelium is p53-negative.
Interestingly, whereas p53-positive cells are weakly positive for AID, a
much stronger AID signal was detected in surrounding p53-negative
cells (Figure 1D).
FTECs of BRCA mutation carriers who underwent RRBSO showed
AID positivity in 33% of the cases (Figure 1, B,G). In most of the cases
examined, the signal intensity score was low.
52% of fimbriae of patients who underwent salpingectomy due to
uterine leiomyoma, who we referred to as controls, had weak tomoderate
AID staining (Figure 1, E, G). Conversely, only 3.5% of the fimbria
Figure 1. AID is expressed in FTECs.Histological sections of fallopian tubeswere immuno-stainedwith either AID antibody (A, B, D, E, F) or p53
antibody (C). Tissueswere derived from patients undergoing salpingectomy for the following indications: HGSOC (A, n=28), RRBSO inBRCA
genemutation carriers (B,n=24), leiomyoma (E,n=27) or ectopic pregnancy (F,n=29). Boxes represent×2enlargementof themarkedarea.
(C, D) Incidental serous tubal intraepithelial carcinoma (STIC) diagnosed in RRBSO specimen from aBRCAmutation carrier. Consecutive slides
were stained for p53 to highlight the lesion (C), and for AID (D). The signal intensity for all cases is graphically summarized (G).
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intensity score (Figure 1, F, G). These differences probably reflect less
ovulation cycles experienced until resection, as the median ages of the
ectopic pregnancy, leiomyoma and RRBSO groups were 33 (range: 20–
45) vs. 52 (range: 38–67) and 43 years (range: 35–66), respectively.Next, we wanted to characterize AID expression in HGSOC
tumors (n = 27). The intensity of AID staining varied considerably:
18.2% of the tumors showed high AID signal, 24.2% of the tumors
were scored as moderate, 30.3% were scored as weak and 27.3% were
negative for AID (Supp. Figure 1). Our data shows greater degree of
Figure 2. AID is up-regulated in inflammatory conditions. Histological sections of inflamed fallopian tubes were immuno-stained with
either AID antibody (A) or p53 antibody (B). Chronic inflammation co-localized with extensive AID and p53 staining. Arrows indicate cells
stained positively for both antibodies.
94 AID Mediates Ovulation-Induced Carcinogenic Effects Sapoznik et al. Neoplasia Vol. 18, No. 2, 2016AID positivity than previously suggested by the TCGA transcrip-
tomic data showing AID mRNA up-regulation in only 3.8–6.4% of
the HGSOC analyzed (cBioPortal analysis [50,51]).
AID is Up-Regulated in Inflammatory Conditions
To study the effect of inflammation, we looked at AID expression in
cases of acute or chronic salpingitis (Figure 2, Supp Figure 2, n = 7). AsFigure 3. Treatment of FTECs with FF induces AID expression. (A) AID
pooled FF. (B) Time course of AID induction following FF pool stimulation
P= .007, 2 h n= 4, P= .28, 4 h n= 7, P= .003, 24 h n= 3, P= .06). (C)
stimulationwith FF pool for 4 h as observed by immunohistochemistry (×
protein expression following incubation with FF pool as observed by wedemonstrated in Figure 2A, chronic inflammatory infiltrate co-localizes
with intense AID staining in FTECs. It also coincides with abundant
TP53-positive cells (Figure 2B), indicating genotoxic stress, TP53
activation or possible initiation of precursor lesions. These results may
suggest a causal association between AID expression and the abundant
TP53-positive pre-malignant lesions in the fallopian tube (‘p53
signatures’) [9].transcription induction following 4 h incubation with individual FF and
from15min to 24 h (15minn=3,Wilcoxon test, P= .64, 45min n=5,
Increased AID protein expression in the cytoplasm of FTECs following
20magnification (top) and×40magnification (bottom)). IncreasedAID
stern blot analysis in FTECs (D), and in iFTECs (E).
Figure 4. Blockade of either TNFα, or estradiol signaling does not
inhibit FF induced AID mRNA induction. Induced AID expression in
FTECs following 4-h incubation of iFTECs with either control medium
(c), FF pool (n = 4, Wilcoxon test P = .021), or TNFα (5 ng/ml, n = 4,
P= .021), aswell as 24-h incubationwith 10 nM β-Estradiol (E2, n=4,
P= .021). Blockade of TNFα by infliximab (inf., 10 μg/ml, n=3), of E2
by fulvestrant (ful., 100 nM, n= 3), or of both factors together (n= 3)
did not attenuate FF inducedAID transcription (P N .05). Controlswere
carried out by incubation of the cells with either fulvestrant (n = 3),
infliximab (n=3), a combination of fulvestrant and infliximab (n=3), a
combination of E2 and fulvestrant (n = 3) or a combination of TNFα
and infliximab (n = 3). Results are presented as fold induction
compared to normal control medium. # represents data that is
significantly different from control, but insignificantly different from
FF-treated cells.
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Induces AID Expression
We hypothesized that exposure of normal human FTECs to FF,
depicting natural ovulation stimuli, up-regulates AID expression. As we
reported previously [13], incubation of FTECs with FF does not
compromise their viability and proliferation. Following 4-h incubation
with FF obtained from different IVF patients, the level of AID mRNA
vs. untreated control was induced by 1.2-fold to 3.6-fold (Figure 3A).
Interestingly, a pool from 6 different FF samples resulted in more
pronounced, 4.1-fold AID mRNA induction, suggesting a synergistic
effect of several FF components. A significant induction of AID by FF
pool was seen as early as after 45 minutes of treatment (Figure 3B, n = 5,
Wilcoxon testP = .007), andwasmaximal following 4-h incubation with
FF pool (n = 7, P = .003). Interestingly, transcription down-regulation
was seen after 24-h treatment. Similarly, up-regulation of AID protein
levels following 4-h stimulation with FF pool is demonstrated by
immunostaining (Figure 3C, n = 3) as well as by western blot analysis
(Figure 3, D, E).
Previous work showed A3B up-regulation in ovarian tumors as
compared to normal ovarian tissues [45]. RT-PCR results indicate that
while the baseline amount of A3BmRNA in FTECswas ~16-fold higher
than that of AID mRNA, no induction of A3B expression was detected
following 15-min to 24-h treatment with FF pool (Supp. Figure 3).
Estradiol and TNFα Redundantly Contribute to FF-Mediated
AID Induction
Human FF contains factors responsible for oocyte maturation and
ovulation, including steroid hormones, growth factors, cytokines and
proteolytic enzymes [52]. Ex vivo induction of AID by estradiol was
previously shown in mouse ovaries [27]. Incubation of iFTECs with
10 nM β-estradiol (E2) for 24 h resulted in 4.8-fold AID mRNA
induction (Figure 4, n = 4, Wilcoxon test P = .021). Pretreatment with
100 nM fulvestrant, an estrogen receptor antagonist, for 24 h completely
repressed the induction of AID by E2 (1.08-fold induction compared to
control, Figure 4, n = 3). To test whether E2 is the major component
responsible for AID elevation, we pretreated iFTECs with fulvestrant as
before, for 24 h prior to incubation with FF pool. Fulvestrant alone and
FF pool alone served as controls. Surprisingly, treatment with fulvestrant
did not significantly decrease FF-mediated AID induction (2.4- vs.
2.8-fold increase in AID mRNA respectively, Figure 4, n = 3).
The pro-inflammatory factor TNFα was previously reported to be
a component of human FF [52]. Stimulation of iFTECs with 5 ng/ml
TNFα resulted in 4.2-fold AID mRNA induction (Figure 4, n = 4,
Wilcoxon test P = .021). 1-h pre-incubation of TNFα with 10 μg/ml
infliximab, an anti-TNFα monoclonal antibody, completely blocked
this effect of TNFα (0.9-fold induction compared to control, n = 3).
However, 1-h incubation of FF pool with 10 μg/ml infliximab, did
not attenuate the observed increase in AID mRNA in comparison to
FF pool alone (3.3- vs. 2.8-fold, Figure 4, n = 3). Lastly, incubation
with both fulvestrant and infliximab did not significantly decrease the
AID-inducing effect of FF (3.3-fold increase, Figure 4, n = 3). These
results suggest that whereas E2 and TNFα are potent AID inducers
neither one is essential, and other FF components may possibly
compensate for their neutralization.
AID is Functional in FF-Treated FTECs
To verify the functionality of AID in FTECs, we performed an
in vitro FRET-based deamination assay (Figure 5A). We measured
37% increase in Cy3 fluorescent signal in FF pool-treated iFTECs ascompared to untreated control (Figure 5B, n = 4, t test P = .01). We
repeated the experiment using stable AID-OE FTECs, which exhibit
more robust and durable effects of AID activation. Following
overexpression of AID, cells were viable and did not show significant
alterations in cell cycle distribution, anchorage independent growth,
or proliferation rate as compared to control (empty vector, data not
shown). Using this system, we measured 20% increase in Cy3
fluorescent signal as compared to control (Figure 5B, n = 2, P = .06).
These results reflect specific deamination of the only cytidine in the
oligonucleotide probe by AID and directly indicate that AID
deamination activity is increased in iFTECs following stimulation
with FF pool, as well as in stably AID-overexpressing cells.
AID Activity Induces a Decrease in Overall DNA Methylation
As AID deamination results in the conversion of methylated
cytidine to thymidine and the repair mechanisms do not restore the
methylation pattern, we used DNA methylation in FTECs as
surrogate for AID activity.
Following short-term incubation with FF pool (4 h), the global
amount of 5 mC was reduced by 28% and 21% in iFTECs (n = 4,
Wilcoxon test P = .02) and FTECs (n = 4, P = .02), respectively
(Figure 5C). Similarly, We observed a 50% reduction in 5 mC levels in
AID-OE FTECs as compared to control (Figure 5C, n = 2, P = .05).
These results indicate that AID is active in FTECs under conditions
similar to physiological ovulation, and that the induced changes in global
DNA methylation are cumulative.
It is noteworthy that AID overexpression in FTECs results in a
modest transcriptional change. Using an oligonucleotide microarray,
at a twofold change cut-off, only 145 genes were up-regulated and 24
genes were down-regulated (Supp. Table 2). This observation is
Figure 5. AID is functional following overexpression, as well as in FF-treated iFTECs. (A) Schematic illustration of FRET-based in vitro
deamination assay. (B) FRET-based in vitro deamination assay using FF pool treated iFTECs (n = 4, P = .014) as well as AID–OE FTECs
(n = 2, P = .06) as compared to untreated controls. Cells were incubated with either AID consensus probe or a control probe for
normalization. (C) Total 5 mC levels in FF pool-treated FTECs (n = 4, Wilcoxon test P = 0.02), FF pool-treated iFTECs (n = 4, P = .02), or
AID-OE FTECs (n= 2, P= .05). (D) Amount of AP sites in FF pool-treated iFTECs, as compared to untreated controls, immediately after 4-h
incubation with FF pool (n = 2, t test P = .19), or after additional 4-h incubation with normal medium (n = 2, t test P = .006).
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transcriptional programs.
AID Induces the Formation of AP Sites in iFTECs
We compared the rate of AP sites in the DNA of iFTECs following
exposure to FF pool. Though not significant, we observed a 26% increase
in the amount of AP sites (from 93.4/105-bases to 117.8/105-bases
(Figure 5D, n = 2, t test P = .19)). The effect was more prominent when
DNA extraction was delayed by 4 h, supposedly accounting for
prolonged AID activity and kinetics of repair processes, leading to 36%
increase in the amount of AP sites (136/105-bases, n = 2, P = .006).
However, the rate of AP sites in DNA extracted from stable AID-OE
FTECs was not significantly greater than in control cells (data not
shown). Unlike deamination of 5 mC, which leads to irreversible loss of
methylation, the formation of AP sites is a transient event, which
undergoes repair before replication, hence is not cumulative.
AID Activity Induces DNA Damage in FTECs
We immunostained AID-OE FTECs, as compared to control cells,
for phospho-Histone H2A.X (γH2A.X) to quantitate dsDNA breaks
(Figure 6, A, B). We observed a 50% increase in γH2A.X positive
cells (t test, P = .007). This data is in accordance with our previous
report showing a similar 70% increase in γH2A.X positive cells
following transient exposure of FTECs to FF pool [13].
To further characterize the DNA damage caused by AID, we
analyzed global chromosomal rearrangements in AID-OE FTECs as
compared to control cells using Affymetrix CytoScan microarrays. Werevealed 149 unique losses and 148 unique gains in AID-OE FTECs,
compared to 96 losses and 69 gains in control cells. The copy number
gains correspond to 1.16% of the genome in AID-OE FTECs vs.
0.31% in the control cells, while the percentage of the genome which
is covered by copy number losses is 0.90% and 0.92% in AID-OE
and control FTECs.
AID Motif Mutagenic Pattern in HGSOC
We analyzed whole-exome sequencing data of 293 HGSOC
samples from TCGA for evidence for AID-related mutagenesis
pattern, as previously reported [40,44]. Applying the bioinformatic
methods described by Roberts et al. [39] to clustered mutations only,
we were unable to detect AID-motif (WRC) enrichment. We did,
however, find 1.82- and 2.39-fold enrichment of A3B-related TC and
TCW motifs respectively (Supp. Figure 4). A statistically significant
enrichment for A3B motif was seen in only 1 out of 293 tumors
analyzed. Both results are in agreement with Roberts et al., in which
only 3 out of 317 ovarian tumors showed enrichment for the A3B
signal [39].
A total of 33,859 somatic mutations were detected in the 293
whole-exome datasets, more than 99% were not clustered. Of these
mutations, 32.5% were C:G → T:A transition, which is the most
prevalent mutational outcome of AID function [18] (Table 1).
Supplementary Table 1 shows the proportion of mutations with
AID-motif out of the total number of mutations detected in each of
the tumors analyzed. The rate of the AID motif in the human exome
(WRCY or RGYW) was calculated by us as 6.6%, while the average
Figure 6. AID activity induces DNA damage in FTECs. (A, B) A 1.5-fold increase in γH2AX staining in AID-OE FTECs (n = 157), vs. control
cells (n = 170) (t test, P = .007, scale-1 μm Red- γH2AX, Blue-DAPI).
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Exact Test P = 4.52e-219). Interestingly, in 7% (21/293 tumors) the
rate of AID-motif mutations was more than 2-fold higher than
expected by random.
Discussion
It is widely accepted that recurrent somatic mutations confer
proliferative advantage to the tumor. Nevertheless, it is still unclear
why specific genes and chromosomal “hotspots” are particularly
susceptible to mutagenesis in multiple different types of tissues.
Significant progress has been made in the past few years in identifying
mutation patterns and defining the concept of ‘kataegis’, clustered
hypermutations [40,44]. Assuming the existence of an endogenous
mutagenic mechanism, AID/APOBEC deaminases have been
suggested as responsible for these catastrophic events [53]. Aside
from genetic predisposition to genomic instability delivered by
BRCA1/2 mutations, very little is known about the molecular drivers
of mutations and genomic instability during serous papillaryTable 1. Distribution of Somatic Mismatch Mutations in HGSOC Tumors. 293 Whole-Exome
Data Sets Were Retrieved From TCGA and the Type of Mismatch Mutation (MM) Was
Quantified. About One Third are C:G → T:A Transitions
MM type Number Percent
C N A 2613 9.294
G N A 4532 16.12
T N A 1401 4.983
A N C 967 3.439
G N C 2389 8.497
T N C 2143 7.622
A N G 2114 7.519
C N G 2342 8.33
T N G 995 3.539
A N T 1428 5.079
C N T 4602 16.368
G N T 2589 9.209
Total 28115 100carcinogesis. Over 40 years ago Fathalla hypothesized that ovulation
causes repeated inflammatory damage followed by cyclic repair of the
ovarian epithelium, culminating in malignant transformation [2].
While the same hypothesis can be easily applied to the fimbria as the
tissue-of-origin, no mechanistic sequence of events has been
delineated yet. In the current study, we investigate the role of AID
in HGSOC using three complementary approaches: In the first part
of this research, we show that AID expression is up-regulated in vivo
under pro-carcinogenic circumstances and in inflammatory condi-
tions in the tissue-of-origin, whereas it is not uniformly highly
expressed in advanced HGSOCs, suggesting a significant role during
the initial steps of the tumorigenic process. In the second part, we
show that AID plays a key role in vitro in instigating genotoxic
damage in the cell-of-origin of HGSOC—the FTEC [9]. To do that,
we uniquely model the effects of normal ovulation, epitomized in this
research in the transient exposure of FTECs to contents of human FF.
Under these unique experimental conditions we observed a
significant, tightly-regulated induction of AID, along with an increase
in dsDNA breaks, AP sites, and genomic rearrangements, and
reduction in global DNA methylation. We have showed that various
FF components, including E2 and TNFα are capable of inducing
AID transcription, but none is indispensable. The kinetics of AID
induction by FF is likely to be the sum of several factors, most are yet
unknown. Finally, in the third part of the research we present a
bioinformatic analysis performed on a large set of HGSOC
sequencing data showing enrichment for somatic mutations that
occur within an AID motif.
Perhaps the most intriguing finding of this work, is that, overall, a
single, transient exposure of FTEC cells to FF, mimicking the
physiological process of normal ovulation, results in robust genotoxic
effect. It is reasonable to speculate that most of the DNA damage is
subsequently resolved both in vitro and in vivo, while a fraction
accumulates and exacerbates with repeat inflammatory insults,
resulting in malignancy. To that end we used AID-OE FTECs and
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were accentuated, representing cumulative permanent genetic and
epigenetic aberrations. We also show that unlike dsDNA damage, AP
sites did not accumulate over time in AID-OE cells, suggesting more
efficient base excision repair mechanisms than that of dsDNA breaks,
previously shown to be inherently delayed in FTECs [10].
In vivo, generalized up-regulation is seen in tissue sections of
fimbria of patients with established HGSOC and salpingitis. Previous
literature indicates that the chronically inflamed colonic mucosa of
patients with inflammatory bowel disease undergoes a ‘field change’
of cancer-associated molecular alterations anteceding the appearance
of dysplasia [54]. Similarly, our data shows that AID is robustly
expressed throughout the epithelium of the fimbria under chronic
inflammatory conditions, accompanied by p53 positivity, and even
more so in regions adjacent to pre-cancerous lesions, suggesting causal
relations. For the first time, we show that AID is active in the
epithelium of the müllerian tract in both benign and malignant
conditions. AID-expressing perturbed FTECs are hence primed for
malignant transformation, after accruing sufficient DNA damage.
As mentioned before, A3B had been associated with epithelial
carcinogenesis, including ovarian cancer (in which only 3 out of 317
tumors showed enrichment for the A3B signal) [39]. Using the same
computational approach, we performed an independent analysis of
somatic mutations in advanced HGSOC tumors from the TCGA, in
search for enrichment for clusters of point mutations associated with
AID motif (WRCY). Nevertheless, our results did not support such
conclusion, in line with previous data, failing to show that AID causes
mutation clustering. To the best of our knowledge there are no
publications demonstrating global enrichment for AID motifs based
on whole-exome sequencing. Any existing data is confined to
preselect cancer-related genes [25,55]. A single research that looked at
AID motif in whole-exome sequencing of gastric carcinoma, alluded
to an unconventional AID motif [30]. It is conceivable that while
AID does not directly form clustered mutations, AID-mediated
dsDNA breaks lead to secondary activation of break-induced
replication and incorporation of random clustered mutations
(without preferential AID-motif) which mask the overall enrichment
for AID motif [44]. This notion is supported by our observations
regarding increased level of DNA breaks and chromosomal
rearrangements in AID-OE FTECs, as well as by vast body of data
regarding the role of AID in class-switch recombination and
chromosomal translocations [20,24]. We do, however, show that
almost one third of the somatic point mutations in HGSOC are C:G
→ T:A transitions, and that mostHGSOC tumors have above-random
frequency of AID-motif mutations.
In conclusion, our research suggests the engagement of AID as the
‘missing link’ between ovulation-induced inflammation, DNA
damage, and carcinogenesis of the fallopian tube epithelium.
Obviously, the process of tumorigenesis extends over many years
and cannot be attributed to a single factor. We highlight a mechanism
by which the repeated physiological process of ovulation may be
considered an endogenous carcinogen leading to HGSOC, necessi-
tating further research in order to better define at-risk populations
and improve early-detection or chemo-prevention in these women.
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